L3VLUP
ProSign in

ICLR · VRTX in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

ICLRVRTX
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • ICLR
  • VRTX
010203040202120222023202420252026
Holders and value by quarter
QuarterICLRVRTX
Q3 202012 holders, $3.0bn31 holders, $21.9bn
Q4 202011 holders, $3.1bn30 holders, $18.4bn
Q1 202114 holders, $3.0bn31 holders, $15.4bn
Q2 202121 holders, $4.2bn30 holders, $12.7bn
Q3 202118 holders, $6.7bn35 holders, $10.1bn
Q4 202117 holders, $8.3bn28 holders, $12.4bn
Q1 202217 holders, $5.6bn23 holders, $16.1bn
Q2 202215 holders, $5.0bn25 holders, $18.1bn
Q3 202212 holders, $4.3bn22 holders, $18.4bn
Q4 202216 holders, $4.5bn28 holders, $18.4bn
Q1 202316 holders, $5.3bn26 holders, $21.4bn
Q2 202317 holders, $5.9bn27 holders, $24.7bn
Q3 202316 holders, $6.0bn33 holders, $24.3bn
Q4 202318 holders, $6.6bn32 holders, $28.6bn
Q1 202421 holders, $8.0bn31 holders, $29.8bn
Q2 202424 holders, $7.7bn29 holders, $33.4bn
Q3 202420 holders, $6.6bn27 holders, $33.5bn
Q4 202422 holders, $4.4bn26 holders, $28.5bn
Q1 202519 holders, $4.3bn21 holders, $35.4bn
Q2 202526 holders, $4.9bn21 holders, $32.3bn
Q3 202521 holders, $4.9bn22 holders, $25.9bn
Q4 202518 holders, $5.3bn26 holders, $31.8bn
Q1 202616 holders, $3.8bn25 holders, $31.8bn
Q2 202615 holders, $6.5bn26 holders, $34.6bn
ICLR

Icon Pub LTD Co

Holders
15
Reported value
$6.5bn
Buyers
19
Sellers
16

Breadth +3 among 91 comparable managers.

Health care services and researchHealthcare: biopharma and medtech · L3VLUP
VRTX

Vertex Pharmaceuticals Inc

Holders
26
Reported value
$34.6bn
Buyers
21
Sellers
17

Breadth +4 among 91 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations

Who holds both, Q2 2026

Among the 34 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only ICLR (8)

Artisan Partners LP, D. E. Shaw & Co., Harris Associates LP, Moore Capital Management LP, Point72 Asset Management LP, Ruane Cunniff & Goldfarb LP, Schonfeld Strategic Advisors LLC, Verition Fund Management LLC

Only VRTX (19)

Acadian Asset Management LLC, AQR Capital Management LLC, Arrowstreet Capital LP, Baillie Gifford & Co, Balyasny Asset Management LLC, Brevan Howard Capital Management LP, Bridgewater Associates LP, Capital Research Global Investors, Citadel Advisors LLC, Holocene Advisors LP, Hudson Bay Capital Management LP, Janus Henderson Group Ltd, Man Group PLC, Marshall Wace LLP, Millennium Management LLC, Neuberger Berman Group LLC, Renaissance Technologies LLC, T. Rowe Price Associates Inc, Two Sigma Investments LP

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →